Slide 1: Cingulate Therapeutics
Cingulate Therapeutics Developing next-generation drug candidates where standard-of- care treatments result in suboptimal outcomes 4Q - 2022 4 & — i CING-US-116-1023
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include all statements, other than stat
Slide 3: Developing Next-Generation Medications in Billion-Dollar Markets
Developing Next-Generation Medications in Billion-Dollar Markets Precision Timed Release™ (PTR™) Platform Unlocks the Possibility for ‘True’ Once-daily, Multi-dose Tablets Immediate Release Film Coat Third Erosion Barrier Release Layers Second Release See the PTR™ Platform in Action Ox ( eR “Symphon
Slide 4: Vast Pipeline of Next-Generation Medications Beyond ADHD
Vast Pipeline of Next-Generation Medications Beyond ADHD VY Leverage PTR platform faster and with less cost in other therapeutics areas Y Market Criteria: O $1Bn+ in peak sales O Next-generation mediations with significant improvement over existing therapies Identified PTR™ Platform Pipeline Opportu
Slide 5: FIRST and ONLY ADHD Medication to Overcome All Unmet Needs
FIRST and ONLY ADHD Medication to Overcome All Unmet Needs Precision Timed Release™ (PTR™) Platform Unlocks the Possibility for ‘True’ Once-daily, Multi-dose Tablets $ 1 8 Fast Onset Billion’ ar Eliminate Need for ‘Booster/Recovery’ Meds US ADHD Eliminate Avoid ‘Wear-off’ Market Rebound/Crash Effect
Slide 6: Targeting Treatment of ADHD - $18Bn US Market Opportunity
Targeting Treatment of ADHD - $18Bn US Market Opportunity Frequently diagnosed, chronic pattern interfering with functioning / development ~17 Million US ADHD Societal Impact of ADH Patients Estimated annual incremental costs of $143 to $266 billion in the United States Adult ADHD Children & Adolesc
Slide 7: $18 Billion US ADHD Market Dominated by Stimulants
$18 Billion US ADHD Market Dominated by Stimulants Stimulants 91% of US Market $15.3Bn' 70 Million Prescriptions per Year’ Y¥_IQVIA Survey of ADHD market found over 60% of providers were currently unsatisfied with available treatment Methylphenidates Amphetamines 7 options? = Ritalin® / LA = Vyvanse
Slide 8: ADHD Market Currently Dominated by Stimulant Products
ADHD Market Currently Dominated by 4 Stimulant Products Major Unmet Medical Needs Persist ADHD BRANDS ATTRIBUTES" UNMET NEEDS" Fast Onset of Duration Action Entire Active- Minimize Onset (less onset) < 30 min Day Efficacy* Crash/Rebound | Avoid Booster? Vyvanse® 2007 2hours 12 hours x x DEN x Availa
Slide 9: ADHD Market Leaders Do Not Provide “Built-In Booster”
ADHD Market Leaders Do Not Provide “Built-In Booster” Market Leaders Stop Delivery of Medication 4-5 Hours After Administration ADHD BRAND ATTRIBUTES' RELEASE PROFILES" fourtcn s on DOSE 1 / STYLE / TIME DOSE 2 / STYLE / TIME DOSE 3 / STYLE /TIME 100% PRODRUG Vyvanse® 2 hours 12 hours SUSTAINED RELE
Slide 10: Recent Launches Lack Meaningful Clinical Innovation
Recent Launches Lack Meaningful Clinical Innovation Niche Delivery Platforms — Designed to Fail in ADHD ADHD BRANDS ATTRIBUTES" UNMET NEEDS Fast Acting Av Avoi Prod: Onset Duratio' (< 30 min) ‘ash/Reboun: Booster x x Quillivant / Chew® XR 60 mins 8 hours x Mydayis® 2or4 hrs 16+ hours ix i x Potentia
Slide 11: The Cingulate Solution for ADHD Patients & Providers
The Cingulate Solution for ADHD Patients & Providers SEMASTERY” YGACCOMPLISH® CTx-1301 CTx-1302 CING-US-116-1023
Slide 12: Nine Significant Points of Differentiation
Nine Significant Points of Differentiation NO ADHD product available today PTR™ technology affords our product candidates combines all unmet needs the following potential advantages over currently available ADHD treatments v Provide ‘entire active-day’ efficacy Vv Reduce abuse / diversion by elimina
Slide 13: CTx-1301 (d-MPH) and CTx-1302 (d-AMP)
CTx-1301 (d-MPH) and CTx-1302 (d-AMP) Ideal Design Provides Exclusive Ability to Overcome Unmet Needs TARGET ATTRIBUTES RELEASE PROFILES 1 | onset | Duration | DOSE 1 / STYLE / TIME DOSE 2 / STYLE / TIME DOSE 3 / STYLE /TIME CTx-1301 F Up to 16 45% SUSTAINED RELEASE OVER 90 20% IMMEDIATE (d-MPH) i h
Slide 14: CTx-1301 Clinical Phase Study Results
CTx-1301 Clinical Phase 2 Study Results Plasma dexmethylphenidate (AMPH) Concentration vs Time Extends duration for ‘entire active-day’ without Low D. o Ose the booster dose! 3000 Results demonstrate fast onset with the desired 2500 Fast Onset controlled descent Minimize ‘crash/rebound’ effect, comm
Slide 15: At the Individual Level, Tri-modal Delivery is Clear
At the Individual Level, Tri-modal Delivery is Clear Entire Active-Day Efficacy, Stop the Crash & Rebound, Eliminate the Booster Dose Subject ID: 01-510 Subject ID: 01-504 3500 —@ = CTx-1301 6.25-mg —@— Focalin XR 5-mg ei 2 0 = CTx-1301 50-mg 00 —®— Focalin XR 40-mg 5 10 18 20 2s 30 10 10 15 45 8 CT
Slide 16: CTx-1301 Demonstrated Significantly Lower Adverse Events
CTx-1301 Demonstrated Significantly Lower Adverse Events 28.6% reduction in TEAE’s related to CTx-1301 versus Focalin XR (14.3% difference) Focalin XR CTx-1301 Focalin XR CTx-1301 All All 5mg 6.25 mg 40 mg 50 mg CTx-1301 Focalin XR (n=41) (n=39) (n=43) (n=42) (n=42) (n=44) Treatment Emergent Adverse
Slide 17: CTx-1301 Clinical and Regulatory Timeline
SMASTERY ° CTx-1301 Clinical and Regulatory Timeline 2022 2023 2024 2025 CLINICAL PHASE 3 Adult Dose- Optimization PHASE 3 Pediatric / Adolescent PHASE 4 Efficacy and Safety Study to Evaluate Onset and Duration n~20 Exploratory Endpoints NDA Preparation and NDA Approval Filing ~1H 2025 Fixed-Dose, P
Slide 18: Commercialization to Drive Revenue
Commercialization to Drive Revenue Changing dynamics in ADHD Maximize Access for Patients and Providers commercial landscape * — Clinical, Practical, and Societal Story: * — Ability to dominate share of voice + Efficacy and Tolerability o Concerta, Adderall XR, Focalin XR are all * One versus Two Pr
Slide 19: Exclusivity: IP, Agreements, and Trade Secrets
Exclusivity: IP, Agreements, and Trade Secrets Intellectual property rights expected to provide exclusivity through 2035 at a minimum . OralogiK™ Erosion Barrier Layer + Five (5) patents granted (US & Global) expiry dates ranging from 2031 to 2035, * One (1) Oralogik™ patent pending (US, Europe) + T
Slide 20: Cingulate Mission
Cingulate Mission Develop... Shape market acceptance, and... Prepare to commercialize next-generation drug candidates... Where currently prescribed standard-of-care treatments result in suboptimal outcomes for all stakeholders Achievement Drives Shareholder and Team Member Value Cingulate.com CINGUL